Garmezy Highlights Ongoing and Future Research Directions Across RCC Subtypes
Benjamin Garmezy, MD, provides an overview of recent data on immuno-oncology/TKI combination data in variant renal cell carcinoma.
Source: onclive.com
Institutional Perspectives News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Institutional Perspectives. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Institutional Perspectives Today - Breaking & Trending Today
Individualized Approach Best Informs Choice of Frontline Immunotherapy or Targeted Therapy Combinations Across RCC Histologies
Benjamin Garmezy, MD, discusses challenges associated with navigating the current frontline armamentarium in both clear cell and variant RCC, the impact of frontline IO doublets and IO/TKI regimens on patient outcomes, and the importance of ongoing combination studies for patients with variant RCC.
Source: onclive.com
Continued Investigations are Pertinent for FDA Approvals in the Treatment of Patients With EGFR-mutated NSCLC
Jason Porter, MD, highlights the implications of recent data to emerge following the use of EGFR TKIs in the adjuvant setting, the importance of the potential upcoming FDA approval of osimertinib with chemotherapy in EGFR-positive non–small cell lung cancer, and more.
Source: onclive.com
Sequencing BCMA-Directed Therapies Expands Multiple Myeloma Treatment Horizons
Sikander Ailawadhi, MD, spotlights the characteristics of multiple myeloma that drive the decision to use teclistamab-cqyv, elranatamab-bcmm, or talquetamab-tgvs.
Source: onclive.com
Research Developments Provide Clarity and Raise Further Questions in Myeloma, Myelofibrosis, DLBCL, and MDS
Sikander Ailawadhi, MD, discusses characteristics of myelofibrosis that influence decisions between JAK inhibitors, highlights differences between bispecific antibodies to consider when managing diffuse large B-cell lymphoma, and more.
Source: onclive.com